Evidence map›Paper›PMID 33708624›Full record

ArticleFrontiers in oncology2021

Diagnostic Utility of IGF2BP1 and Its Targets as Potential Biomarkers in ETV6-RUNX1 Positive B-Cell Acute Lymphoblastic Leukemia.

Gunjan Sharma, Elza Boby, Thakur Nidhi, Ayushi Jain, Jay Singh, Archna Singh, Parthaprasad Chattopadhyay, Sameer Bakhshi, Anita Chopra, Jayanth Kumar Palanichamy

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. IGF2BPs as novel mGenes & diseases · 2024
    Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Gunjan SharmaDepartment of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
Elza BobyDepartment of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
Thakur NidhiDepartment of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
Ayushi JainDepartment of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
Jay SinghDepartment of Laboratory Oncology, Dr. B.R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.
Archna SinghDepartment of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
Parthaprasad ChattopadhyayDepartment of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
Sameer BakhshiDepartment of Medical Oncology, Dr. B.R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.
Anita ChopraDepartment of Laboratory Oncology, Dr. B.R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.
Jayanth Kumar PalanichamyDepartment of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
All India Institute of Medical Sciences · INDR. B.R.A. Institute Rotary Cancer Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Around 85% of childhood Acute Lymphoblastic Leukemia (ALL) are of B-cell origin and characterized by the presence of different translocations including

Indexed as

B-ALLEGFL7ETV6-RUNX1 translocationIGF2BP1receiver operating characteristic curve (ROC)

Identifiers

PMID33708624
PMCPMC7940665
OpenAlexW3130937022

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.